BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11489498)

  • 1. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes.
    Ríhová B; Etrych T; Pechar M; Jelínková M; Stastný M; Hovorka O; Kovár M; Ulbrich K
    J Control Release; 2001 Jul; 74(1-3):225-32. PubMed ID: 11489498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
    Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
    J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
    Etrych T; Jelínková M; Ríhová B; Ulbrich K
    J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
    Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
    Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
    Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
    J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene.
    Ríhová B; Jelínková M; Strohalm J; St'astný M; Hovorka O; Plocová D; Kovár M; Dráberová L; Ulbrich K
    Bioconjug Chem; 2000; 11(5):664-73. PubMed ID: 10995209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic action of doxorubicin bound to the polymeric carrier based on N-(2-hydroxypropyl)methacrylamide copolymers through an amide or hydrazone bond.
    Ríhová B; Etrych T; Sírová M; Kovár L; Hovorka O; Kovár M; Benda A; Ulbrich K
    Mol Pharm; 2010 Aug; 7(4):1027-40. PubMed ID: 20524698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
    Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
    Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
    J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
    Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
    J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
    Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
    Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
    Etrych T; Mrkvan T; Ríhová B; Ulbrich K
    J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
    Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
    J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
    Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
    J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy.
    Etrych T; Kovář L; Strohalm J; Chytil P; Ríhová B; Ulbrich K
    J Control Release; 2011 Sep; 154(3):241-8. PubMed ID: 21699933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
    Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
    J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
    David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
    Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
    Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
    J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.